Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 2/20 | 0.44 |
| ▸ | FDPS | P14324 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 4/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL8915833 | 0.92 | DNM1 (0.44) | SMPD1FDPSTP53DNM1EPHX1 | |
| SCHEMBL3626235 | 0.88 | DNM1 (0.50) | SMPD1FDPSDNM1EPHX1MEN1 | |
| SCHEMBL37785 | 0.88 | DNM1 (0.50) | SMPD1FDPSDNM1EPHX1MEN1 | |
| SCHEMBL37599 | 0.88 | DNM1 (0.50) | SMPD1FDPSDNM1EPHX1MEN1 | |
| SCHEMBL3619992 | 0.88 | DNM1 (0.50) | SMPD1FDPSDNM1EPHX1MEN1 | |
| SCHEMBL6029725 | 0.88 | DNM1 (0.50) | SMPD1FDPSDNM1EPHX1MEN1 | |
| SCHEMBL11938906 | 0.85 | DNM1 (0.46) | SMPD1FDPSDNM1EPHX1MEN1 | |
| Sulfuric Acid SCHEMBL6200765 | 0.81 | TP53 (0.41) | FDPSTP53CA1CA2EPHX1 | |
| SCHEMBL29222649 | 0.79 | DNM1 (0.57) | SMPD1FDPSDNM1EPHX1MEN1 | |
| SCHEMBL3627331 | 0.79 | DNM1 (0.57) | SMPD1FDPSDNM1EPHX1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241005-A1 | Encapsulation of cannabinoids | PRECISIOBIOTIX TECHNOLOGIES INC. (CA) | 2023-08-03 | — | — | US | claimed |
| US-20240325316-A1 | Encapsulation of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | PRECISIO BIOTIX THERAPEUTICS INC (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240238570-A1 | METHODS FOR BETTER DELIVERY OF ACTIVE AGENTS TO TUMORS | SOFUSA HOLDINGS LLC | 2024-07-18 | — | — | US | disclosed |
| US-20240181235-A1 | METHODS FOR LYMPHATIC DELIVERY OF ACTIVE AGENTS | SOFUSA HOLDINGS LLC | 2024-06-06 | — | — | US | disclosed |
| US-11911463-B2 | Topical hyper-allergenic composition and method of treating using the same | ALLEAMIT INC. | 2024-02-27 | — | — | US | disclosed |
| US-20230241005-A1 | Encapsulation of cannabinoids | PRECISIOBIOTIX TECHNOLOGIES INC. (CA) | 2023-08-03 | — | — | US | disclosed |
| US-11607407-B2 | Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use | RELMADA THERAPEUTICS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-3925599-A1 | METHODS FOR BETTER DELIVERY OF ACTIVE AGENTS TO TUMORS | Sorrento Therapeutics, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3922238-A1 | METHODS FOR LYMPHATIC DELIVERY OF ACTIVE AGENTS | Sorrento Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3325081-B1 | METHODS FOR LYMPHATIC DELIVERY OF ACTIVE AGENTS | SORRENTO THERAPEUTICS INC (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-2557924-B1 | DERMAL PHARMACEUTICAL COMPOSITIONS OF 1-METHYL-2',6'-PIPECOLOXYLIDIDE AND METHOD OF USE | RELMADA THERAPEUTICS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20180193624-A1 | METHODS FOR BETTER DELIVERY OF ACTIVE AGENTS TO TUMORS | SORRENTO THERAPEUTICS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180193625-A1 | METHODS FOR LYMPHATIC DELIVERY OF ACTIVE AGENTS | SORRENTO THERAPEUTICS, INC. | 2018-07-12 | — | — | US | disclosed |
| EP-3325081-A2 | METHODS FOR LYMPHATIC DELIVERY OF ACTIVE AGENTS | Kimberly-Clark Worldwide, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325080-A2 | METHODS FOR BETTER DELIVERY OF ACTIVE AGENTS TO TUMORS | Kimberly-Clark Worldwide, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20170333410-A1 | Dermal Pharmaceutical Compositions of 1-Methyl-2',6'-Pipecoloxylidide and Method of Use | RELMADA THERAPEUTICS, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| WO-2017019535-A2 | METHODS FOR LYMPHATIC DELIVERY OF ACTIVE AGENTS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017019526-A2 | METHODS FOR BETTER DELIVERY OF ACTIVE AGENTS TO TUMORS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| EP-2557924-A1 | DERMAL PHARMACEUTICAL COMPOSITIONS OF 1-METHYL-2',6'-PIPECOLOXYLIDIDE AND METHOD OF USE | Relmada Therapeutics, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130455-A1 | DERMAL PHARMACEUTICAL COMPOSITIONS OF 1-METHYL-2',6'-PIPECOLOXYLIDIDE AND METHOD OF USE | BABUL NAJIB (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333410-A1 | Dermal Pharmaceutical Compositions of 1-Methyl-2',6'-Pipecoloxylidide and Method of Use | PIP4K2C, PIP5K1C, PIP4K2A | SMPD1 126/4885FDPS 1732/4885TP53 1890/4885 |
| US-11607407-B2 | Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use | PIP4K2C, PIP5K1C, PIP4K2A | SMPD1 130/4885FDPS 1795/4885TP53 1986/4885 |
| US-20240325316-A1 | Encapsulation of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | PTGES, PTGS2, PTGS1 | SMPD1 2636/4885FDPS 569/4885TP53 2407/4885 |
| US-20230241005-A1 | Encapsulation of cannabinoids | CNR2, CNR1, FAAH | SMPD1 835/4885FDPS 801/4885TP53 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.